News

News
August 07, 2019
Glycomine, Inc. Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Disease of Glycosylation …

Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced that it has raised $33 million in a Series B financing led by Novo Holdings A/S. Proceeds from the financing will be used to advance Glycomine's substrate replacement therapy for PMM2-CDG (CDG-1a), the most prevalent form in the spectrum of congenital diseases of glycosylation (CDG), into early stage clinical studies....

Learn More +

November 16, 2016
Glycomine, Inc. Announces $12 Million Series A Financing to Advance a New Generation of Replacement Therapies for Rare Diseases

Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rare diseases, today announced that it has raised $12 million in a Series A financing led by Sanderling Ventures and supported by Chiesi Ventures as well as existing high net worth individuals and patients. Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (PMM2-CDG), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1)...

Learn More +